These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 6541738)

  • 1. [Prostaglandin treatment of ductus-dependent congenital heart defects].
    Olsson B; Björkhem G; Lundström NR
    Lakartidningen; 1984 Oct; 81(40):3619-22. PubMed ID: 6541738
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].
    Fujii S; Nagai I; Yonei A; Sari A; Baba K
    Masui; 1984 May; 33(5):545-9. PubMed ID: 6540818
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostaglandins and the management of congenital heart disease.
    Taylor WJ; Alpert BS
    Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1].
    Lillquist K
    Ugeskr Laeger; 1979 Jul; 141(28):1915-6. PubMed ID: 473414
    [No Abstract]   [Full Text] [Related]  

  • 5. The ductus arteriosus: why and how to manipulate its patency.
    Drummond WH; Bucciarelli RL; Gessner IH
    J Fla Med Assoc; 1983 Sep; 70(9):788-93. PubMed ID: 6355376
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostaglandin treatment of newborns with ductal-dependent congenital heart disease.
    Linday LA; Engle MA
    Pediatr Ann; 1981 Apr; 10(4):29-38. PubMed ID: 7232040
    [No Abstract]   [Full Text] [Related]  

  • 7. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS; Nihill MR; Titus JL
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
    Kertész E; Hencz P; Tekulics P; Beviz J; Száva J; Matkó I; Kovács G
    Orv Hetil; 1980 May; 121(20):1197-9. PubMed ID: 7413203
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn.
    Olley PM; Coceani F; Rowe RD; Swyer PR
    Adv Prostaglandin Thromboxane Res; 1980; 7():913-6. PubMed ID: 6768235
    [No Abstract]   [Full Text] [Related]  

  • 10. [Long-term treatment using prostaglandin E2 in congenital heart defects with the pulmonary circulation being supplied by a patent ductus arteriosus].
    Hruda J; Samánek M; First T; Vorísková M; Skovránek J
    Cesk Pediatr; 1985 May; 40(5):257-62. PubMed ID: 3860302
    [No Abstract]   [Full Text] [Related]  

  • 11. [Skeletal side effects of treatment with prostaglandin E1].
    Persigehl M; Hövels-Gürich H; von Bernuth G
    Rofo; 1984 Oct; 141(4):427-30. PubMed ID: 6436918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comments on the pharmacologic manipulation of the ductus arteriosus in newborns.
    Rowe RD
    Adv Prostaglandin Thromboxane Res; 1978; 4():383-5. PubMed ID: 645513
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA; Clyman RI
    Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular therapy in the newborn.
    Sandor GG
    Clin Invest Med; 1985; 8(4):360-7. PubMed ID: 3907921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostaglandin E1 in newborn infants with ductus-dependent heart diseases. Review of 40 cases].
    Simões LC; Sarachaga IH; Quero M; Casanova M; Cazzaniga M; Villibre D
    Arq Bras Cardiol; 1985 Jul; 45(1):31-6. PubMed ID: 3938651
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of prostaglandin E1 in ductus-dependent congenital cardiopathies].
    Marcial MB; Maluf M; Atik E; Vargas H; Baucia JA; Verginelli G
    Arq Bras Cardiol; 1983 Jun; 40(6):383-6. PubMed ID: 6686760
    [No Abstract]   [Full Text] [Related]  

  • 17. [Analogs of prostaglandin-related substances and inhibitors of their formation and metabolism. Clinical application to the pediatric field--arteries and prostaglandins].
    Honda S
    Nihon Rinsho; 1985 Mar; 43(3):603-7. PubMed ID: 3892092
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of prostaglandins in cardiopulmonary diseases of the newborn.
    Olley PM; Coceani F
    Semin Perinatol; 1980 Apr; 4(2):135-41. PubMed ID: 6990504
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostaglandin E1 in neonates with critical congenital heart disease.
    Dungan WT; Norton JB; Readinger RI; Sotomora RF
    J Ark Med Soc; 1982 Oct; 79(5):167-70. PubMed ID: 6183249
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease.
    Freed MD; Heymann MA; Lewis AB; Roehl SL; Kensey RC
    Circulation; 1981 Nov; 64(5):899-905. PubMed ID: 7285305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.